{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-26-000019","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2026-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.025000+00:00","generated_at":"2026-05-16T07:59:56.020221+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Autolus enters 10-year lentiviral vector supply deal with AGC Biologics","bullets":["Master Service Agreement with AGC Biologics for lentiviral vector, critical for CAR-T production.","Minimum purchase: 14 batches in first 2 years; EUR 25 million over subsequent 5 years.","AGC granted first right to negotiate manufacturing of obe-cel (obecabtagene autoleucel).","10-year fixed term, non-exclusive; Autolus can terminate with certain fees, either party for default.","Agreement replaces prior arrangement; individual work orders govern specific projects."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-26-000019","json":"https://secwatch.observer/filing/0001730463-26-000019.json","markdown":"https://secwatch.observer/filing/0001730463-26-000019.md","text":"https://secwatch.observer/filing/0001730463-26-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000019/0001730463-26-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000019/autl-20260121.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T07:59:56.020221+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cb8456faf656c2af96aa40b1908de204eaa51c8f","claim":"Autolus Therapeutics plc entered into Master Service Agreement with AGC Biologics S.p.A. valued at EUR 25 million (effective 2026-01-21).","evidence_excerpt":"On January 21, 2026, Autolus Limited, a wholly owned subsidiary of Autolus Therapeutics plc (the “ registrant ”, and together with Autolus Limited, the “ Company ”), entered into a Master Service Agreement with AGC Biologics S.p.A (“ AGC ”) for the manufacture and supply of lentiviral vector (the “ Agreement ”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000019/0001730463-26-000019-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"AGC Biologics S.p.A."},{"label":"Value","value":"EUR 25 million"},{"label":"Effective","value":"2026-01-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}